Why Cardiff Oncology Stock Is Rising After Hours
Portfolio Pulse from Ryan Gustafson
Cardiff Oncology, Inc. (NASDAQ:CRDF) shares traded higher in after-hours following the announcement of positive clinical data from its ongoing trials in metastatic pancreatic ductal adenocarcinoma and small cell lung cancer. The company also revealed plans for a mPDAC first-line investigator-initiated trial of the combination of onvansertib plus standard-of-care.
September 26, 2023 | 9:28 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cardiff Oncology's stock rose after the company announced positive clinical data and plans for a new trial. This could potentially increase investor confidence in the company's future prospects.
The positive clinical data from Cardiff Oncology's ongoing trials and the announcement of a new trial could potentially lead to new treatments, which would increase the company's value. This news is likely to have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100